Clinical trial NCT00891384: Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
Official title: A Randomised Comparison of Daily 25 mg Versus 5 mg Lenalidomide as Maintenance Therapy After High-dose Therapy and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Multiple Myeloma
Keywords: Multiple Myeloma
maintenance therapy
lenalidomide
Lead sponsor: Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Sponsor class: OTHER
First posted: 2009-05-01
Enrollment: 194
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial is a randomised, parallel-group, multicenter phase III study for maintenance therapy with lenalidomide in patients with multiple myeloma who were treated with high-dose therapy and autologous stem cell transplantation as first line therapy.

Detailed description: High-dose therapy will be performed as first line treatment. After high-dose therapy and autologous stem cell transplantation the patients will be included and randomised. Three month after high-dose therapy all patients will receive consolidation therapy with 6 cycles of lenalidomide 25 mg daily for 21 days every 28 days. Afterwards patients will receive maintenance therapy according to their assigned treatment arm. Randomisation will be performed in a 1:1 ratio to continuous maintenance therapy with either 25mg or 5mg lenalidomide daily for 21 days every 28 days.Randomisation will be stratified by ISS-stage (1+2 vs 3, age (younger than 66 years versus 66 years or older), response after high-dose therapy (CR+vgPR vs PR vs MR/SD. Patients will be treated until disease progression.

Eligibility criteria: Inclusion Criteria:

* Signed informed consent form
* Age 18-75 years
* Able to adhere to the study visit schedule and other protocol requirements
* Patients with multiple myeloma who have received high-dose therapy and autologous stem cell transplantation as first-line therapy within the last 90 - 120 days and have not shown progressive disease afterwards.
* Patients may have received up to 6 cycles of prior induction therapy and up to 2 cycles of prior mobilisation chemotherapy. A bortezomib or thalidomide induction therapy is allowed. Patients may also have received prior radiation therapy
* Measurable levels of myeloma paraprotein in serum (\>0.5 g/dL) or urine (\>0.2 g/24hours) or measurable free light chains (FLC) in serum (\>50 mg/l) with an abnormal FLC ratio must be documented at the time of first diagnosis.
* ECOG performance status = 2 at study entry
* Laboratory and functional test results within these ranges:

  * ANC ≥ 1,000/μL
  * Platelet count ≥ 100,000/μL
  * Total bilirubin 2.5 mg/dL
  * AST (SGOT) and ALT (SGPT) 3 x ULN
  * Patients with impaired renal function can be included
* The patient must be able to adhere to the pregnancy precautions
* Disease free of prior malignancies for 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast

Exclusion Criteria:

* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
* Pregnant or breast feeding females
* Any condition or laboratory abnormality which places the subject at an unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
* Known allergic/hypersensitivity reaction to thalidomide, lenalidomide or any components of the treatment
* Any cutaneous grade ≥ 3 adverse reaction (for example desquamating rash) while taking thalidomide or similar drugs
* Any prior use of lenalidomide
* Known positive for HIV or active infectious hepatitis, type A, B or C

Primary outcomes:
measure: event-free survival
timeFrame: 6 years
Secondary outcomes:
measure: safety, tolerability and feasibility
timeFrame: 6 month
measure: Improvement of remission rate
timeFrame: 6 years
measure: evaluate quality of life
timeFrame: 6 years
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: Medizinische Klinik, Abteilung Innere Medizin
state: Baden-Württemberg
city: Giessen
country: Germany
facility: Clinic of Justus-Liebig-University, Medical Clinic for Hematology and Medical Oncology
state: Hessen
city: Duesseldorf
country: Germany
facility: Departement of Hematology, Oncology and Clinical Immunology
state: Northwest
city: Duisburg
country: Germany
facility: St. Johannes Hospital, Medical Clinic II
state: Northwest
city: Hamburg
country: Germany
facility: Bone Marrow Transplantation Unit, University Hospital Hamburg-Eppendorf
Study officials:
affiliation: Departement of Hematology, Oncology and Clinical Immunology
name: Guido Kobbe, PD Dr.
role: PRINCIPAL_INVESTIGATOR
References: